# Nantes University Hospital (CHU de Nantes)

Source: https://onco.cc/institutions/chu-nantes/  
OnCo record `chu-nantes` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The university hospital of Nantes, whose haematology department under Philippe Moreau is one of the two French centres that lead the Intergroupe Francophone du Myélome trials.

## Summary

The CHU de Nantes is the university hospital of Nantes in western France; its Hôtel-Dieu site houses the Department of Hematology, led by Philippe Moreau. With Lille, Nantes anchors the Intergroupe Francophone du Myélome, and Moreau was first author of the IKEMA and MAIA-era trials and of the 2022 New England Journal of Medicine report of teclistamab in relapsed myeloma. The Institut de Cancérologie de l'Ouest, the region's dedicated cancer centre, is a separate institution.

## Fields

- Kind: Institution
- Last checked: 2026-09-18
- Also known as: Hôtel-Dieu de Nantes; CHU Nantes; University Hospital Hôtel-Dieu
- City: Nantes, FR
- Type: hospital
- Website: https://www.chu-nantes.fr

## Sources

- CHU de Nantes: https://www.chu-nantes.fr

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- institutions: [Institut de Cancérologie de l'Ouest (ICO)](https://onco.cc/institutions/ico-angers-nantes/)
- people: [Philippe Moreau](https://onco.cc/people/philippe-moreau/)

---
JSON: https://onco.cc/api/v1/entities/chu-nantes.json